ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft

• Main Authors: Jasinghe, V.J., Xie, Z., Zhou, J., Khng, J., Poon, L.-F., Senthilnathan, P., Chen, C.-S., Albert, D.H., Davidsen, S.K.
• Other Authors: MEDICINE
• Format: Article
• Published: 2011
• Subjects: ABT-869; Angiogenesis; Hepatocellular carcinoma; mTOR pathway; Rapamycin; Tyrosine kinase inhibitor
• Online Access: http://scholarbank.nus.edu.sg/handle/10635/26815
• Institution: National University of Singapore

10.1016/j.jhep.2008.08.010